SK Biotek Co. Ltd. has reached a definitive agreement to buy Bristol-Myers Squibb Co.’s small molecule active pharmaceutical ingredient (API) manufacturing facility in Swords, Ireland, as part of its plan to boost production capacity and have a production base in Europe to help a planned transformation into a leading global contract manufacturing organization.
"This will be our first overseas manufacturing plant. We are aiming to sharply raise revenue and corporate value by 2020,...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
